ONCO-INNOVATION
PROGRAMME

The Onco-Innovation programme, part of the CRUK Cambridge Centre, is administered by
Dr Rebecca Harris
at the Milner Therapeutics Institute. The programme focuses on the application of multidisciplinary science to progress pre-clinical cancer research and aims to build a more cohesive flow between pre-clinical research and clinical impact.

We would love to hear from you! Use the button below to get in touch.

The Onco-Innovation programme, part of the CRUK Cambridge Centre, is administered by
Dr Rebecca Harris
at the Milner Therapeutics Institute. The programme focuses on the application of multidisciplinary science to progress pre-clinical cancer research and aims to build a more cohesive flow between pre-clinical research and clinical impact.

We would love to hear from you! Contact r.harris@milner.cam.ac.uk.

The Onco-Innovation Programme focuses on 3 key areas:

Research

– Disease signature identification and target validation through the
Centre for Pathway Analysis

– Integration of clinical engagement early in discovery research through the CRUK Cambridge Centre

Industry Engagement and Collaboration

– Facilitate pre-clinical industry-academic collaboration across the CRUK Cambridge Centre

– Leverage industry network of the Milner Consortium

10 pre-clinical projects established within the CRUK Cambridge Centre (view projects)

Entrepreneurship and Training

– The MTI is home to accelerator
Start Codon with a number of oncology-focused start-ups

– Oncology companies based within the MTI benefit from facilities & collaborative environment

– We promote training & entrepreneurship through events such as TGIO

Research

– Disease signature identification and target validation through the
Centre for Pathway Analysis

– Integration of clinical engagement early in discovery research through the CRUK Cambridge Centre

Industry Engagement and Collaboration

– Facilitate pre-clinical industry-academic collaboration across the CRUK Cambridge Centre

– Leverage industry network of the Milner Consortium

10 pre-clinical projects established within the CRUK Cambridge Centre (view projects)

Entrepreneurship and Training

– The MTI is home to accelerator
Start Codon with a number of oncology-focused start-ups

– Oncology companies based within the MTI benefit from facilities & collaborative environment

– We promote training & entrepreneurship through events such as TGIO

Discover our Research:

Programme Contacts

Professor Tony Kouzarides
tk106@cam.ac.uk
Dr Susan Galbraith
Susan.Galbraith@astrazeneca.com
Dr Rebecca Harris
r.harris@milner.cam.ac.uk

 

Publications

1.
Sigitas Mikutis, Muxin Gu, Erdem Sendinc, Madoka E. Hazemi, Hannah Kiely-Collins, Demetrios Aspris, George S. Vassiliou, Yang Shi, Konstantinos Tzelepis, and Gonçalo J. L. Bernardes. meCLICK-Seq, a Substrate-Hijacking and RNA Degradation Strategy for the Study of RNA Methylation ACS Central ScienceDOI: 10.1021/acscentsci.0c01094

This paper describes a small molecule-based platform to hijack RNA methylation by guided degradation for high resolution profiling of modified substrates. This breakthrough will allow better mapping of RNA modifications in living cells. The methodology should also permit other translational modifications in RNA and eventually also DNA.

 

2.
Tzelepis K, Rausch O, Kouzarides T. RNA-modifying enzymes and their function in a chromatin context. Nat Struct Mol Biol. 2019 Oct;26(10):858-862. doi: 10.1038/s41594-019-0312-0. Epub 2019 Oct 3. PMID: 31582848.

This paper discusses the potential for novel drug targets, which may lead to relevant patient therapies.

 

3.
David A. Russell, Hannah R. Bridges, Riccardo Serreli, Sarah L. Kidd, Natalia Mateu, Thomas J. Osberger, Hannah F. Sore, Judy Hirst, and David R. Spring Hydroxylated Rotenoids Selectively Inhibit the Proliferation of Prostate Cancer Cells. Journal of Natural Products 2020 83 (6), 1829-1845 DOI: 10.1021/acs.jnatprod.9b01224

Prostate cancer is one of the leading causes of cancer-related death in men. The identification of new therapeutics to selectively target prostate cancer cells is therefore vital.

 

4.
Li, J. Conde, A. Guerreiro, G. J. L. Bernardes Tetrazine Carbon Nanotubes for Pretargeted In Vivo “Click‐to‐Release” Bioorthogonal Tumour Imaging. Angew. Chem. Int. Ed. 2020, 59, 16023-16032. DOI:10.1002/anie.202008012

This publication demonstrates an approach through which real-time, non-invasive tumour visualization can be achieved, through the tumour-specific delivery of active imaging agents and anticancer drugs. This has both diagnostic and therapeutic applications.

 

5.
Wein S, Andrews B, Sachsenberg T, Santos-Rosa H, Kohlbacher O, Kouzarides T, Garcia BA, Weisser H. A computational platform for high-throughput analysis of RNA sequences and modifications by mass spectrometry. Nat Commun. 2020 Feb 17;11(1):926. doi: 10.1038/s41467-020-14665-7. PMID: 32066737; PMCID: PMC7026122.

This publication presents a free and open-source database search engine for RNA MS data, called NucleicAcidSearchEngine (NASE).

 

6.
Najgebauer H, Yang M, Francies HE, Pacini C, Stronach EA, Garnett MJ, Saez-Rodriguez J, Iorio FCELLector: Genomics-Guided Selection of Cancer In Vitro Models. Cell Systems. 2020 May;10(5):424-432.e6. DOI: 10.1016/j.cels.2020.04.007.

This publication presents CELLEctor, an R package and R Shiny application to allow researchers to select the most relevant cancer cell lines in a patient-genomic-guided fashion. The goal is to allow researchers to choose appropriate in vitro models for inclusion or exclusion in retrospective analyses and future studies.

[Onco-innovation members are highlighted in bold]

Pin It on Pinterest